Sign in Subscribe
Cytology

HIV-1 Tat(1-72) Protein-Coated Nanoparticles Elicit Strong T Cell Type-1 Immune Responses

Strategic Insights

— 1 min read

Scientists in the United States have reported a significant breakthrough in HIV-1 vaccine research. A novel anionic nanoparticle coated with the HIV-1 Tat(1-72) protein was found to generate strong T cell type-1 immune responses in mice. This finding is promising for the development of HIV-1 vaccines, as Tat(1-72) is a conserved regulatory HIV-1 protein and previous studies have suggested that it may be a promising approach for HIV vaccine strategies. The researchers demonstrated that the Tat(1-72) protein-coated nanoparticles were not immunosuppressive, unlike the Tat(1-86) protein, and elicited Th1 biased immune responses.

Key Takeaways:

  • The novel anionic nanoparticle coated with the HIV-1 Tat(1-72) protein generated strong T cell type-1 immune responses in mice.
  • The Tat(1-72) protein-coated nanoparticles were not immunosuppressive when co-administered to mice with ovalbumin (OVA).
  • The immunization of BALB/c mice with Tat-coated nanoparticles resulted in antibody levels (IgG and IgM) comparable to those elicited from Tat and Alum, but led to a Th1 biased immune response.
  • The IFN-gamma release from splenocytes with Tat-coated nanoparticles was comparable to that from mice immunized with Tat and Lipid A, and 3.3-fold greater than that from mice immunized with Tat and Alum.
  • The study warrants further investigation of these nanoparticles to enhance both antibody and cellular-based immune responses.

Statistics:

  • 15 mcg of Tat(1-72) protein was coated on novel anionic nanoparticles for immunization.
  • Antibody and cytokine release were determined in mice on day 28.
  • The IFN-gamma release from splenocytes with Tat-coated nanoparticles was 3.3-fold greater than that from mice immunized with Tat and Alum.

Sources:

  • Cui, Z., et al. "Strong T cell type-1 immune responses to HIV-1 Tat(1-72) protein-coated nanoparticles." Vaccine, vol. 22, no. 20, 2004, pp. 2631-2640. Elsevier Science Ltd.
  • Mumper, R. J. Center for Pharmaceutical Science and Technology, College of Pharmacy, University of Kentucky, Lexington, KY 40536-0082, USA. E-mail: rjmump2@email.uky.edu.

Read more